Press Releases
LONDON, UK, July 14, 2022 – Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on treating iron deficiency with its lead product Accrufer®/Feraccru®, announces that Health Canada have screened and accepted the Accrufer® New Drug Submission (“NDS”), filed by Shield’s Licensing Partner, KYE Pharmaceuticals Inc. (“KYE”) earlier this year.
July 14, 2022 at 2:00 AM EDT
MISSISSAUGA, ON, May 24, 2022 – KYE Pharmaceuticals Inc. (“KYE”), a private company headquartered in Mississauga, Ontario and focused on bringing medicines that fulfill clinically significant unmet needs to the Canadian market, today announced that John McKendry has joined KYE as President.
May 24, 2022 at 9:00 AM EDT
MISSISSAUGA, ON, Mar 21, 2022 – KYE Pharmaceuticals Inc. (“KYE”), a private company headquartered in Mississauga, Ontario and focused on bringing medicines that fulfill clinically significant unmet needs to the Canadian market, today announced it has submitted a New Drug Submission (NDS) to Health Canada for the regulatory review and approval of Accrufer® (ferric maltol).
Mar 21, 2022 at 08:30 AM EDT
MISSISSAUGA, ON, Mar 11, 2022 – Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases and KYE Pharmaceuticals Inc. (“KYE”), a private company focused on bringing medications that fulfill clinically significant and unmet needs to the Canadian market, today announced receipt of a favorable decision from the Federal Court of Canada (“Court”) setting aside for the second time the decision of Canada’s national healthcare regulatory agency, Health Canada, to approve Ruzurgi® (amifampridine) for Lambert-Eaton Myasthenic Syndrome (“LEMS”) patients.
Mar 11, 2022 at 08:03 AM ET
MISSISSAUGA, ON, Jan 05, 2022 – Shield Therapeutics plc (LSE: STX), a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), announces that it has entered into an exclusive licence agreement (“the Agreement”) for Accrufer® with KYE Pharmaceuticals Inc. (“KYE”) in Canada.
Jan 05, 2022 at 08:10 AM EDT
MISSISSAUGA, ON, June 03, 2021 (CANADA NEWSWIRE) – KYE Pharmaceuticals Inc. (“KYE”) today announced a positive decision in their lawsuit in Canadian Federal Court challenging Health Canada’s approval of Medunik’s New Drug Submission (NDS) for Ruzurgi®.
June 03, 2021 at 3:10 PM EDT
MISSISSAUGA, ON, May 04, 2021 (CANADA NEWSWIRE) – CORZYNA™ (ranolazine extended-release tablets) has now been made commercially available and is in wholesalers across Canada after a positive expedited review by Health Canada.
May 04, 2021 at 8:30 AM EDT
CORZYNA™ is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies
January 5, 2021 at 9:00 AM EDT
MISSISSAUGA, ON, October 28, 2020 (CANADA NEWSWIRE) – KYE Pharmaceuticals Inc. (“KYE”), a private company headquartered in Mississauga, Ontario focused on bringing medicines that fulfill clinically significant unmet needs to the Canadian market, today announced an important milestone, FIRDAPSE® …
October 28, 2020 at 10:40 AM EDT
August 26, 2020 at 9:40 AM EDT
CORAL GABLES, Fla., Aug. 18, 2020 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular …
August 18, 2020 at 8:03 AM EDT
MONMOUTH JUNCTION, N.J. and MISSISSAUGA, Ontario, July 9, 2020 /CNW/ — Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and …
July 09, 2020, 07:30 ET